These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28655306)

  • 1. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    Birlie B; Braekers R; Awoke T; Kasim A; Shkedy Z
    BMC Infect Dis; 2017 Jun; 17(1):453. PubMed ID: 28655306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-state Markov model for time to treatment changes for HIV/AIDS patients: a retrospective cohort national datasets, Ethiopia.
    Kumsa TH; Mulu A; Beyene J; Asfaw ZG
    BMC Infect Dis; 2024 Jun; 24(1):627. PubMed ID: 38914968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
    Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM
    BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
    Siegfried NL; Van Deventer PJ; Mahomed FA; Rutherford GW
    Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD004535. PubMed ID: 16625606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND; Bader J; Lejone TI; Ringera I; Puga D; Glass TR; Klimkait T
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study.
    Ayele T; Jarso H; Mamo G
    AIDS Res Ther; 2017 Feb; 14(1):5. PubMed ID: 28143541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
    Madruga JR; Cassetti I; Suleiman JM; Etzel A; Zhong L; Holmes CB; Cheng AK; Enejosa J;
    HIV Clin Trials; 2007; 8(6):381-90. PubMed ID: 18042503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal.
    Soorju V; Naidoo P
    Afr J Prim Health Care Fam Med; 2016 Oct; 8(1):e1-e6. PubMed ID: 28155312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Reason for Regimen Change Among HIV/AIDS Patients Initiated on First Line Highly Active Antiretroviral Therapy in Southern Ethiopia.
    Woldemedhin B; Wabe NT
    N Am J Med Sci; 2012 Jan; 4(1):19-23. PubMed ID: 22393543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Durability and tolerability of long-term nevirapine-based HAART].
    Giacometti A; Butini L; Cirioni O; Costantini A; Montroni M; Scalise G
    Infez Med; 2010 Mar; 18(1):20-6. PubMed ID: 20424522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
    Kumarasamy N; Vallabhaneni S; Cecelia AJ; Yepthomi T; Balakrishnan P; Saghayam S; Flanigan TP; Carpenter CC; Solomon S; Mayer KH
    J Acquir Immune Defic Syndr; 2006 Jan; 41(1):53-8. PubMed ID: 16340473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database.
    Zhou J; Paton NI; Ditangco R; Chen YM; Kamarulzaman A; Kumarasamy N; Lee CK; Li PC; Merati TP; Phanuphak P; Pujari S; Vibhagool A; Zhang F; Chuah J; Frost KR; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):8-16. PubMed ID: 17305926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
    Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
    Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study.
    Ankrah DNA; Lartey M; Mantel-Teeuwisse AK; Leufkens HGM
    BMC Infect Dis; 2017 Oct; 17(1):664. PubMed ID: 28969591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Causes for antiretroviral regimen change among HIV/AIDS patients in Addis Ababa, Ethiopia.
    Jima YT; Angamo MT; Wabe NT
    Tanzan J Health Res; 2013 Jan; 15(1):11-8. PubMed ID: 26591668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of two anti-antiretroviral protocols used for treatment of a cohort of HIV 1-positive patients followed at the Institute of Public Health and Hygiene in Dakar, Senegal].
    Sow PG; Dia AT; Diallo PD; Traore ; Gaye AM
    Med Trop (Mars); 2011 Apr; 71(2):202-3. PubMed ID: 21695888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
    Zhang Z; Lin Q; Xu Y; Guan W; Song X; Li Y; Zhang Y; Li T; Yu W
    Arch Osteoporos; 2023 Apr; 18(1):48. PubMed ID: 37041320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
    Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K
    Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.